HCWB
$0.87-0.07 (-7.46%)
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW921...
Recent News
BC-Most Active Stocks
YY Group Holdings Ltd. 26,117,734 0.0511
Wall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment Report
US stocks look set to open little changed in Friday's trading session ahead of consumer sentiment da
Consumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session
US stock futures were little changed in Friday's premarket session ahead of consumer sentiment and o
HCW Biologics Second Quarter 2025 Earnings: US$0.90 loss per share (vs US$16.16 loss in 2Q 2024)
NasdaqCM:HCWB 1 Year Share Price vs Fair Value Explore HCW Biologics's Fair Values from the Community and select yours...
Insiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9m
The recent 14% drop in HCW Biologics Inc.'s ( NASDAQ:HCWB ) stock could come as a blow to insiders who purchased...